Literature DB >> 21114327

Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4.

David Nguyen1, Padmaja Dhanasekaran, Margaret Nickel, Ryosuke Nakatani, Hiroyuki Saito, Michael C Phillips, Sissel Lund-Katz.   

Abstract

Human apolipoprotein (apo) E4 binds preferentially to very low-density lipoproteins (VLDLs), whereas apoE3 binds preferentially to high-density lipoproteins (HDLs), resulting in different plasma cholesterol levels for the two isoforms. To understand the molecular basis for this effect, we engineered the isolated apoE N-terminal domain (residues 1-191) and C-terminal domain (residues 192-299) together with a series of variants containing deletions in the C-terminal domain and assessed their lipid and lipoprotein binding properties. Both isoforms can bind to a phospholipid (PL)-stabilized triolein emulsion, and residues 261-299 are primarily responsible for this activity. ApoE4 exhibits better lipid binding ability than apoE3 as a consequence of a rearrangement involving the segment spanning residues 261-272 in the C-terminal domain. The strong lipid binding ability of apoE4 coupled with the VLDL particle surface being ∼60% PL-covered is the basis for its preference for binding VLDL rather than HDL. ApoE4 binds much more strongly than apoE3 to VLDL but less strongly than apoE3 to HDL(3), consistent with apoE-lipid interactions being relatively unimportant for binding to HDL. The preference of apoE3 for binding to HDL(3) arises because binding is mediated primarily by interaction of the N-terminal helix bundle domain with the resident apolipoproteins that cover ∼80% of the HDL(3) particle surface. Thus, the selectivity in the binding of apoE3 and apoE4 to HDL(3) and VLDL is dependent upon two factors: (1) the stronger lipid binding ability of apoE4 relative to that of apoE3 and (2) the differences in the nature of the surfaces of VLDL and HDL(3) particles, with the former being largely covered with PL and the latter with protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21114327      PMCID: PMC3025481          DOI: 10.1021/bi1017655

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  36 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Effect of carboxyl-terminal truncation on structure and lipid interaction of human apolipoprotein E4.

Authors:  Masafumi Tanaka; Charulatha Vedhachalam; Takaaki Sakamoto; Padmaja Dhanasekaran; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal:  Biochemistry       Date:  2006-04-04       Impact factor: 3.162

3.  Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins.

Authors:  L M Dong; K H Weisgraber
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

4.  Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli.

Authors:  J A Morrow; K S Arnold; K H Weisgraber
Journal:  Protein Expr Purif       Date:  1999-07       Impact factor: 1.650

5.  Examination of lipid-bound conformation of apolipoprotein E4 by pyrene excimer fluorescence.

Authors:  Jessica Drury; Vasanthy Narayanaswami
Journal:  J Biol Chem       Date:  2005-02-11       Impact factor: 5.157

6.  A monomeric, biologically active, full-length human apolipoprotein E.

Authors:  Yonghong Zhang; Sheeja Vasudevan; Radiya Sojitrawala; Wentao Zhao; Chunxian Cui; Chao Xu; Daping Fan; Yvonne Newhouse; Reeny Balestra; W Gray Jerome; Karl Weisgraber; Qianqian Li; Jianjun Wang
Journal:  Biochemistry       Date:  2007-08-23       Impact factor: 3.162

7.  Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms.

Authors:  Danny M Hatters; Madhu S Budamagunta; John C Voss; Karl H Weisgraber
Journal:  J Biol Chem       Date:  2005-08-01       Impact factor: 5.157

8.  Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.

Authors:  K H Weisgraber
Journal:  J Lipid Res       Date:  1990-08       Impact factor: 5.922

9.  Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization.

Authors:  J A Westerlund; K H Weisgraber
Journal:  J Biol Chem       Date:  1993-07-25       Impact factor: 5.157

10.  Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms.

Authors:  L M Dong; C Wilson; M R Wardell; T Simmons; R W Mahley; K H Weisgraber; D A Agard
Journal:  J Biol Chem       Date:  1994-09-02       Impact factor: 5.157

View more
  32 in total

1.  Fluorescence analysis of the lipid binding-induced conformational change of apolipoprotein E4.

Authors:  Chiharu Mizuguchi; Mami Hata; Padmaja Dhanasekaran; Margaret Nickel; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal:  Biochemistry       Date:  2012-07-03       Impact factor: 3.162

2.  Enhanced binding of apolipoprotein A-I variants associated with hypertriglyceridemia to triglyceride-rich particles.

Authors:  Irina N Gorshkova; David Atkinson
Journal:  Biochemistry       Date:  2011-02-20       Impact factor: 3.162

3.  O-glycosylation on cerebrospinal fluid and plasma apolipoprotein E differs in the lipid-binding domain.

Authors:  Sarah A Flowers; Oliver C Grant; Robert J Woods; G William Rebeck
Journal:  Glycobiology       Date:  2020-01-28       Impact factor: 4.313

4.  Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels.

Authors:  Hui Li; Padmaja Dhanasekaran; Eric T Alexander; Daniel J Rader; Michael C Phillips; Sissel Lund-Katz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-14       Impact factor: 8.311

5.  Helical structure, stability, and dynamics in human apolipoprotein E3 and E4 by hydrogen exchange and mass spectrometry.

Authors:  Palaniappan S Chetty; Leland Mayne; Sissel Lund-Katz; S Walter Englander; Michael C Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

6.  Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease.

Authors:  Carl Frieden; Kanchan Garai
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

Review 7.  New insights into the determination of HDL structure by apolipoproteins: Thematic review series: high density lipoprotein structure, function, and metabolism.

Authors:  Michael C Phillips
Journal:  J Lipid Res       Date:  2012-12-10       Impact factor: 5.922

Review 8.  APOE in the normal brain.

Authors:  Sarah A Flowers; G William Rebeck
Journal:  Neurobiol Dis       Date:  2020-01-03       Impact factor: 5.996

9.  Peptide-Level Interactions between Proteins and Small-Molecule Drug Candidates by Two Hydrogen-Deuterium Exchange MS-Based Methods: The Example of Apolipoprotein E3.

Authors:  Hanliu Wang; Don L Rempel; Daryl Giblin; Carl Frieden; Michael L Gross
Journal:  Anal Chem       Date:  2017-09-25       Impact factor: 6.986

10.  Human ApoE ɛ2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase.

Authors:  Sarah K Woody; Helen Zhou; Shaher Ibrahimi; Yafeng Dong; Liqin Zhao
Journal:  J Alzheimers Dis       Date:  2016-06-18       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.